Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine, Université de Toulouse, Toulouse, France.
Eur J Clin Pharmacol. 2012 May;68(5):857-65. doi: 10.1007/s00228-011-1198-x. Epub 2011 Dec 29.
Underreporting of adverse drug reactions is common but has been rarely studied in Parkinson's disease (PD).
To compare the prevalence of adverse events (AEs) in relation to antiparkinsonian drugs in PD patients using two different data collection methods: patient's spontaneous reporting versus a predefined investigator-driven structured interview. Secondary objectives were to assess factors related to spontaneous reporting and to compare the rate of AE reporting in PD patients with that of a group of non-parkinsonian post-stroke patients.
Cross-sectional study.
Ambulatory, cognitively intact PD or post-stroke outpatients.
None.
Patients were first asked by means of an an open question to disclose any unpleasant effects in connection with their current medications that had occurred during the previous week. Afterwards, a predefined questionnaire listing the most common AEs known to be related to antiparkinsonian drugs was used to question the same patients in a systematic manner about the presence of any AE during the same week. Chronological and semiological criteria were used to classify the reported AEs as "unrelated" or "possibly/plausibly related" to the antiparkinsonian treatment.
A total of 203 PD and 52 post-stroke patients of comparable age and sex were recruited. Eighty-five PD and five post-stroke patients reported spontaneously at least one AE (42 vs. 10%, p < 0.01), while 203 PD and 47 post-stroke patients reported at least one AE following the structured questionnaire (100 vs. 90%, p < 0.001). In PD patients, there were a total of 112 spontaneously reported AEs as compared with 1,574 according to the structured questionnaire (7%). Spontaneous disclosure of AEs was associated with experiencing >2 AEs [OR = 1.2 (1.1-3.2)], logistic regression). Seventy-four percent of PD patients had ≥1 AE possibly/plausibly related to antiparkinsonian drugs.
Results showed that only 7% of AEs were reported spontaneously by patients, thus underscoring the importance of systematically asking about AEs in PD patients.
药物不良反应(Adverse Drug Reactions,ADRs)漏报较为常见,但在帕金森病(Parkinson's Disease,PD)中鲜有研究。
使用两种不同的数据收集方法,即患者自发报告与预先设定的研究者驱动的结构化访谈,比较与抗帕金森药物相关的不良事件(Adverse Events,AEs)在 PD 患者中的发生率。次要目标是评估与自发报告相关的因素,并比较 PD 患者与非帕金森卒中后患者的 AEs 报告率。
横断面研究。
门诊、认知功能正常的 PD 或卒中后患者。
无。
首先,通过开放式问题询问患者,在过去一周内与当前药物相关的任何不适反应。然后,使用预先设定的问卷列出已知与抗帕金森药物相关的最常见 AEs,以系统地询问同一患者在同一周内是否存在任何 AE。根据时间和症状学标准,将报告的 AEs 分类为与抗帕金森治疗“无关”或“可能/似有关”。
共纳入 203 例 PD 患者和 52 例卒中后患者,年龄和性别相当。85 例 PD 患者和 5 例卒中后患者自发报告至少 1 例 AE(42%比 10%,p<0.01),而 203 例 PD 患者和 47 例卒中后患者根据结构化问卷报告至少 1 例 AE(100%比 90%,p<0.001)。在 PD 患者中,自发报告的 AEs 共计 112 例,而根据结构化问卷报告的 AEs 为 1574 例(7%)。AE 的自发报告与经历>2 种 AE 相关[比值比(OR)=1.2(1.1-3.2)],逻辑回归)。74%的 PD 患者有≥1 种可能/似与抗帕金森药物相关的 AE。
结果表明,只有 7%的 AEs 由患者自发报告,因此强调了在 PD 患者中系统询问 AEs 的重要性。